herbal homeostatic; New innovation for rapid control of bleeding

Cresilon Biotechnology, based in Brooklyn, has received FDA approval for its herbal hemostatic gel. This innovative gel is able to control moderate to severe bleeding in a very short period of time. Tromagel, the name of this product, is the first hemostatic medical device with temporary external use to obtain FDA approval. This gel is designed to temporarily stop blood flow in external wounds.

Compared to other hemostatic products on the market, Tromagel has significant advantages. This herbal gel comes in a pre-filled syringe and is easy to use. Also, it does not require special preparation and is effective in different types of bleeding.

“The ability to quickly stop bleeding at the scene can be the difference between life and death for an injured person,” said Joe Landolina, CEO and founder of Cresilon. FDA approval for Tromagel is a big step towards saving human lives and improving treatment standards in emergency medicine. As an innovative technology, Tromagel has revolutionized the field of bleeding control. This herbal gel, with its unique features, can be effective in emergency situations and save the lives of many people.